Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.05
TRIB's Cash to Debt is ranked lower than
63% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TRIB: 1.05 )
Ranked among companies with meaningful Cash to Debt only.
TRIB' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 114.47 Max: No Debt
Current: 1.05
Equity to Asset 0.59
TRIB's Equity to Asset is ranked lower than
52% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TRIB: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
TRIB' s Equity to Asset Range Over the Past 10 Years
Min: 0.29  Med: 0.75 Max: 0.88
Current: 0.59
0.29
0.88
Interest Coverage 6.44
TRIB's Interest Coverage is ranked lower than
77% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. TRIB: 6.44 )
Ranked among companies with meaningful Interest Coverage only.
TRIB' s Interest Coverage Range Over the Past 10 Years
Min: 0.73  Med: 149.30 Max: 1315.33
Current: 6.44
0.73
1315.33
F-Score: 4
Z-Score: 2.86
WACC vs ROIC
8.17%
7.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 14.34
TRIB's Operating margin (%) is ranked higher than
87% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. TRIB: 14.34 )
Ranked among companies with meaningful Operating margin (%) only.
TRIB' s Operating margin (%) Range Over the Past 10 Years
Min: -56.78  Med: 10.36 Max: 67.5
Current: 14.34
-56.78
67.5
Net-margin (%) 22.65
TRIB's Net-margin (%) is ranked higher than
94% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. TRIB: 22.65 )
Ranked among companies with meaningful Net-margin (%) only.
TRIB' s Net-margin (%) Range Over the Past 10 Years
Min: -55.5  Med: 9.98 Max: 67.4
Current: 22.65
-55.5
67.4
ROE (%) 11.44
TRIB's ROE (%) is ranked higher than
79% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. TRIB: 11.44 )
Ranked among companies with meaningful ROE (%) only.
TRIB' s ROE (%) Range Over the Past 10 Years
Min: -76.72  Med: 7.27 Max: 54.77
Current: 11.44
-76.72
54.77
ROA (%) 8.01
TRIB's ROA (%) is ranked higher than
83% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. TRIB: 8.01 )
Ranked among companies with meaningful ROA (%) only.
TRIB' s ROA (%) Range Over the Past 10 Years
Min: -45.03  Med: 5.95 Max: 41.2
Current: 8.01
-45.03
41.2
ROC (Joel Greenblatt) (%) 43.14
TRIB's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. TRIB: 43.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TRIB' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -123.61  Med: 24.91 Max: 125.23
Current: 43.14
-123.61
125.23
Revenue Growth (3Y)(%) 8.00
TRIB's Revenue Growth (3Y)(%) is ranked higher than
62% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. TRIB: 8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TRIB' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.9  Med: 0.10 Max: 108.2
Current: 8
-30.9
108.2
EBITDA Growth (3Y)(%) 0.30
TRIB's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. TRIB: 0.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TRIB' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.8  Med: 1.60 Max: 125.1
Current: 0.3
-45.8
125.1
EPS Growth (3Y)(%) 1.10
TRIB's EPS Growth (3Y)(%) is ranked higher than
52% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. TRIB: 1.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TRIB' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.9  Med: -0.50 Max: 75.7
Current: 1.1
-52.9
75.7
» TRIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

TRIB Guru Trades in Q1 2015

Chuck Royce 371,000 sh (+1.42%)
Zeke Ashton 135,000 sh (unchged)
Jim Simons 246,954 sh (-24.00%)
» More
Q2 2015

TRIB Guru Trades in Q2 2015

Chuck Royce 519,298 sh (+39.97%)
Jim Simons 268,363 sh (+8.67%)
Zeke Ashton 120,000 sh (-11.11%)
» More
Q3 2015

TRIB Guru Trades in Q3 2015

Chuck Royce 596,098 sh (+14.79%)
Jim Simons 219,196 sh (-18.32%)
Zeke Ashton 77,500 sh (-35.42%)
» More
Q4 2015

TRIB Guru Trades in Q4 2015

Chuck Royce 702,598 sh (+17.87%)
Jim Simons 202,065 sh (-7.82%)
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.29
TRIB's P/E(ttm) is ranked higher than
87% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.35 vs. TRIB: 17.29 )
Ranked among companies with meaningful P/E(ttm) only.
TRIB' s P/E(ttm) Range Over the Past 10 Years
Min: 2.08  Med: 21.62 Max: 69.1
Current: 17.29
2.08
69.1
Forward P/E 21.19
TRIB's Forward P/E is ranked lower than
65% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.92 vs. TRIB: 21.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.94
TRIB's PE(NRI) is ranked higher than
95% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. TRIB: 10.94 )
Ranked among companies with meaningful PE(NRI) only.
TRIB' s PE(NRI) Range Over the Past 10 Years
Min: 2.08  Med: 21.11 Max: 48.33
Current: 10.94
2.08
48.33
P/B 1.30
TRIB's P/B is ranked higher than
79% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. TRIB: 1.30 )
Ranked among companies with meaningful P/B only.
TRIB' s P/B Range Over the Past 10 Years
Min: 0.18  Med: 1.32 Max: 3.56
Current: 1.3
0.18
3.56
P/S 2.35
TRIB's P/S is ranked lower than
52% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. TRIB: 2.35 )
Ranked among companies with meaningful P/S only.
TRIB' s P/S Range Over the Past 10 Years
Min: 0.16  Med: 1.44 Max: 6.93
Current: 2.35
0.16
6.93
POCF 14.53
TRIB's POCF is ranked higher than
69% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.46 vs. TRIB: 14.53 )
Ranked among companies with meaningful POCF only.
TRIB' s POCF Range Over the Past 10 Years
Min: 1.91  Med: 15.55 Max: 89.71
Current: 14.53
1.91
89.71
EV-to-EBIT 8.24
TRIB's EV-to-EBIT is ranked higher than
87% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.84 vs. TRIB: 8.24 )
Ranked among companies with meaningful EV-to-EBIT only.
TRIB' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.7  Med: 16.40 Max: 75.8
Current: 8.24
-1.7
75.8
EV-to-EBITDA 8.24
TRIB's EV-to-EBITDA is ranked higher than
77% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.36 vs. TRIB: 8.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
TRIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.7  Med: 15.70 Max: 75.8
Current: 8.24
-1.7
75.8
Shiller P/E 43.53
TRIB's Shiller P/E is ranked lower than
62% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. TRIB: 43.53 )
Ranked among companies with meaningful Shiller P/E only.
TRIB' s Shiller P/E Range Over the Past 10 Years
Min: 1.33  Med: 17.16 Max: 163
Current: 43.53
1.33
163
Current Ratio 8.54
TRIB's Current Ratio is ranked higher than
87% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. TRIB: 8.54 )
Ranked among companies with meaningful Current Ratio only.
TRIB' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 2.92 Max: 9.17
Current: 8.54
1
9.17
Quick Ratio 6.67
TRIB's Quick Ratio is ranked higher than
83% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. TRIB: 6.67 )
Ranked among companies with meaningful Quick Ratio only.
TRIB' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.59 Max: 7.6
Current: 6.67
0.44
7.6
Days Inventory 243.49
TRIB's Days Inventory is ranked lower than
93% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. TRIB: 243.49 )
Ranked among companies with meaningful Days Inventory only.
TRIB' s Days Inventory Range Over the Past 10 Years
Min: 180.54  Med: 207.68 Max: 262.75
Current: 243.49
180.54
262.75
Days Sales Outstanding 97.65
TRIB's Days Sales Outstanding is ranked lower than
77% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. TRIB: 97.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRIB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.9  Med: 65.88 Max: 87.22
Current: 97.65
47.9
87.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.32
TRIB's Dividend Yield is ranked higher than
68% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. TRIB: 2.32 )
Ranked among companies with meaningful Dividend Yield only.
TRIB' s Dividend Yield Range Over the Past 10 Years
Min: 0.72  Med: 1.02 Max: 2.34
Current: 2.32
0.72
2.34
Dividend Payout 0.24
TRIB's Dividend Payout is ranked higher than
73% of the 51 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. TRIB: 0.24 )
Ranked among companies with meaningful Dividend Payout only.
TRIB' s Dividend Payout Range Over the Past 10 Years
Min: 0.63  Med: 1.18 Max: 2.22
Current: 0.24
0.63
2.22
Dividend Growth (3y) 30.10
TRIB's Dividend Growth (3y) is ranked higher than
80% of the 25 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. TRIB: 30.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
TRIB' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 30.1
Current: 30.1
0
30.1
Forward Dividend Yield 2.36
TRIB's Forward Dividend Yield is ranked higher than
65% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.49 vs. TRIB: 2.36 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.32
TRIB's Yield on cost (5-Year) is ranked higher than
56% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.58 vs. TRIB: 2.32 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TRIB' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.72  Med: 1.02 Max: 2.34
Current: 2.32
0.72
2.34
3-Year Average Share Buyback Ratio -2.20
TRIB's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.80 vs. TRIB: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TRIB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -79.2  Med: -4.95 Max: 26.2
Current: -2.2
-79.2
26.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 11.25
TRIB's Price/Net Current Asset Value is ranked higher than
82% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. TRIB: 11.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TRIB' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.61  Med: 3.21 Max: 320
Current: 11.25
0.61
320
Price/Tangible Book 4.97
TRIB's Price/Tangible Book is ranked higher than
89% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.88 vs. TRIB: 4.97 )
Ranked among companies with meaningful Price/Tangible Book only.
TRIB' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.4  Med: 2.52 Max: 225
Current: 4.97
0.4
225
Price/Projected FCF 1.83
TRIB's Price/Projected FCF is ranked higher than
95% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.92 vs. TRIB: 1.83 )
Ranked among companies with meaningful Price/Projected FCF only.
TRIB' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.28  Med: 1.59 Max: 78.33
Current: 1.83
0.28
78.33
Price/Median PS Value 1.65
TRIB's Price/Median PS Value is ranked higher than
51% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. TRIB: 1.65 )
Ranked among companies with meaningful Price/Median PS Value only.
TRIB' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 1.11 Max: 4.8
Current: 1.65
0.16
4.8
Price/Graham Number 1.55
TRIB's Price/Graham Number is ranked higher than
92% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.53 vs. TRIB: 1.55 )
Ranked among companies with meaningful Price/Graham Number only.
TRIB' s Price/Graham Number Range Over the Past 10 Years
Min: 0.27  Med: 1.15 Max: 9.78
Current: 1.55
0.27
9.78
Earnings Yield (Greenblatt) (%) 12.18
TRIB's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. TRIB: 12.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TRIB' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 5.50 Max: 84.7
Current: 12.18
1.3
84.7
Forward Rate of Return (Yacktman) (%) -22.10
TRIB's Forward Rate of Return (Yacktman) (%) is ranked lower than
96% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. TRIB: -22.10 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TRIB' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -30.5  Med: -2.40 Max: 2.5
Current: -22.1
-30.5
2.5

More Statistics

Revenue(Mil) $102
EPS $ 0.55
Beta0.84
Short Percentage of Float7.52%
52-Week Range $9.20 - 19.69
Shares Outstanding(Mil)23.58

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 101 103
EPS($) 0.47 0.44
EPS without NRI($) 0.47 0.44

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TRBA.Germany,
Trinity Biotech PLC was incorporated as a public limited company, registered in Ireland in January 1992. The Company commenced operations in 1992 and, in October 1992, completed an initial public offering of its securities in the US. The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. It is also a provider of raw materials to the life sciences industry. The Company markets its portfolio of almost 850 products to customers in approximately 100 countries around the world through its own sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's tests remains the USA. The Company develops, acquires, manufactures and markets clinical in-vitro diagnostic products. It supplies the clinical laboratory segment of the in-vitro diagnostic market. It also sells raw materials to the life sciences industry. Its Point-of-Care product is Unigold (tm), which tests for the presence of HIV antibodies. It sells its product through its own direct sales-force in four countries: the United States, Germany, France and the United Kingdom. Its competitors are Abbott Diagnostics, Alere Inc., Arkray, Bio-Rad, Diasorin Inc., Euroimmun, Johnson & Johnson, OraSure Technologies Inc., Phadia, Roche Diagnostics, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen. The preclinical and clinical testing, manufacture, labelling, distribution, and promotion of Trinity Biotech's products are subject to extensive and rigorous government regulation in the United States and in other countries in which its products are sought to be marketed.
» More Articles for TRIB

Headlines

Articles On GuruFocus.com
Zeke Ashton Sells Greenlight Capital and Vector Group, Buys Parker and Alphabet Nov 23 2015 

More From Other Websites
Barron's Recap: The New King Of Video Dec 28 2015
[$$] Time to Lighten Up on Post Holdings Dec 26 2015
Trinity Biotech Announces Q3 2015 Financial Results Dec 17 2015
Trinity Biotech Announces FDA Submission of High Sensitivity Troponin I Product Dec 17 2015
Hedge Funds Are Selling Tetraphase Pharmaceuticals Inc (TTPH) Dec 14 2015
TRINITY BIOTECH PLC Financials Dec 08 2015
Is Trinity Biotech plc (ADR) (TRIB) An Unheralded Micro-Cap Stock Worth Owning? Dec 02 2015
What Do Hedge Funds Think of Akari Therapeutics PLC (ADR) (AKTX)? Nov 27 2015
Is The York Water Company (YORW) A Good Stock To Buy? Nov 24 2015
Oculus Innovative Sciences Beats Analyst Expectations, Even More than at First Blush Nov 12 2015
4 Unusual-Volume Stocks Triggering Big Breakout Trades Nov 02 2015
Trinity Biotech Plc Earnings Q3, 2015 Oct 26 2015
Trinity Biotech Announces Q2 2015 Financial Results Oct 23 2015
Edited Transcript of TRIB earnings conference call or presentation 22-Oct-15 3:00pm GMT Oct 22 2015
Trinity Biotech (TRIB): Moving Average Crossover Alert Sep 02 2015
Trinity Biotech Plc Earnings Q2, 2015 Aug 27 2015
Edited Transcript of TRIB earnings conference call or presentation 28-Jul-15 3:00pm GMT Jul 29 2015
Trinity Biotech to Announce Q2 2015 Financial Results Jul 28 2015
Trinity Biotech Announces Q1 2015 Financial Results Jul 23 2015
Trinity Biotech to Announce Q2 2015 Financial Results Jul 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK